Brean Murray Carret & Co. Starts Insulet Corporation (PODD) at Buy; Attractive Growth Story With Key Approval Near Term

Brean Murray Carret & Co. initiates coverage on Insulet Corporation (NASDAQ: PODD) with a Buy. PT $24.00.

Brean analyst says, "Insulet is uniquely positioned in the $1B insulin pump market as the only supplier of a disposable patch insulin pump, the OmniPod, a highly differentiated product offering which has gained a strong following due to its ease of use and ease of training, among other features. A next gen version of the pump, EROS, finally appears close to FDA clearance, and further improves upon the existing technology - delivering a significant size reduction to wearers and a notable reduction in cost of goods. We expect the cost savings to enable the company to invest incrementally behind the product near term and allow the company to achieve profitability during 2013."

For an analyst ratings summary and ratings history on Insulet Corporation click here. For more ratings news on Insulet Corporation click here.

Shares of Insulet Corporation closed at $19.11 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• UBS Starts Schrodinger (SDGR) at Neutral